Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...
FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and dosage goals.
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...
The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...
PYLARIFY TruVu™ (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and ...
The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving scanning access through increased production ...
An investigational approach to diagnosis of prostate cancer uses sound waves to extract "bubbles of information" from cells. ...
A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results